We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

EUROIMMUN AG

Euroimmun (part of Revvity) is an international provider of medical laboratory products for autoimmune, infection, al... read more Featured Products: More products

Download Mobile App




Euroimmun and Xpedite Diagnostics Partner to Offer Faster, Easier Protocols for DNA Extraction at POC

By LabMedica International staff writers
Posted on 19 Dec 2023

EUROIMMUN (Lübeck, Germany) and Xpedite Diagnostics (Hallbergmoos, Germany) have entered into a strategic partnership for offering faster and easier protocols for DNA extraction at the point-of-care. More...

Current users of the EUROArray diagnostic platform will now have access to the EUROArray SwiftX-traction Kit designed for rapid manual DNA extraction. EUROArray SwiftX-traction significantly reduces the complexity as well as processing time of the DNA extraction. It can extract DNA from different challenging sample types using just a few steps that take less than 30 minutes.

The new extraction method is currently being validated in combination with various CE-marked EUROArray products. Xpedite Diagnostics aims to soon register the extraction kit itself as a CE-IVD device under the European IVD Regulation 2017/746. Xpedite Diagnostics’ partnership with EUROIMMUN demonstrates its technical leadership in offering high-performing and user-friendly nucleic acid extraction solutions. This, combined with its strong expertise in quality management and regulatory affairs, makes Xpedite Diagnostics well-positioned to act as a reliable and efficient contract developer as well as manufacturer for other IVD companies.

“EUROArray SwiftX-traction was tailored specifically to the needs of users of the EUROArray diagnostic platform and is based on our SwiftX Toolbox,” said Dr. Andy Wende, CEO and Head of R&D at Xpedite Diagnostics GmbH. “The development was finished in only a few months and will result in a CE-IVD marked DNA extraction kit. It merges several advantages such as high sensitivity, short workflows, and improved usability. EUROArray SwiftX-traction will enhance customer satisfaction and acceptance, ultimately leading to a better sales position of the EUROArray diagnostic platform in the segments Dermatomycosis, STI testing, and HPV typing.”

Related Links:
EUROIMMUN 
Xpedite Diagnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i6000
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.